Impact of fluvastatin on hyperlipidemia after renal transplantation.

Abstract

BACKGROUND:

Renal transplant recipients are at increased risk of atherosclerotic vascular disease with hyperlipidemia. Many recipients have preexisting cardiovascular disease at the time of transplantation, and immunosuppressive therapy may aggravate existing risk factors or promote development of new risk factors, notably hyperlipidemia and hypertension. Fluvastatin is one of the statins, an HMG-CoA reductase inhibitor, which has been shown to be effective in lowering cholesterol levels. We treated hyperlipidemia after renal transplantation with Fluvastatin for more than 6 months. We attempted to clarify the efficacy of fluvastatin on hyperlipidemia in renal transplant recipients.

MATERIALS:

Forty-five renal transplant recipients with hyperlipidemia were enrolled in this study. The mean age was 44.2 years, with 23 men and 22 women. Thirty-seven transplantations were from a living related donors and eight from cadaveric donors. Thirty-three recipients were ABO-compatible, seven recipients had minor mismatches, and five recipients were ABO-incompatible. The dose of fluvastatin was 20 mg per day. Levels of total cholesterol (TC), triglyceride (TG), HDL cholesterol (HDL-C), LDL cholesterol (LDL-C), serum creatinine (s-Cr), ALT, ALP, uric acid (UA), hematocrit (Ht), CPK, and blood pressure were examined in all recipients before treatment as well as 1, 3, and 6 months after Fluvastatin administration.

RESULTS:

The mean levels of TC and TG were significantly reduced from 256, to 224 and 215 mg/dL, and from 188 to 170 and 147 mg/dL at 1 and 6 months after treatment, respectively. The mean levels of HDL-C were 72 mg/dL before treatment, 81 mg/dL at 1 month, and 80 mg/dL at 6 months after treatment. The mean levels of LDL-C were 153 mg/dL before treatment, 145 mg/dL at 1 month, and 145 mg/dL at 6 months after treatment. Fluvastatin significantly produced a reduction rate in TC of 16%, TG of 22%, and LDL-C of 5% after 6 months of treatment, respectively. The mean levels of HDL-C of were increased 10% after 6 months of treatment. The serum creatinine and CPK were not significantly different. There were no clinically significant differences in other factors. No significant adverse effects were observed.

CONCLUSIONS:

Fluvastatin seemed to be safe and highly effective to control TC, TG, LDL-C, and HDL-C in renal transplant recipients.

• Authors: T Tokumoto, K Tanabe, H Ishida, H Shimmura, N Ishikawa, N Goya, T Akiba, H Toma
• Journal: Transplantation proceedings (Transplant Proc) Vol. 36 Issue 7 Pg. 2141-4 (Sep 2004) ISSN: 0041-1345 [Print] United States
• PMID: 15518777 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Anticholesteremic Agents
• Cholesterol, HDL
• Cholesterol, LDL
• Fatty Acids, Monounsaturated
• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Indoles
• Triglycerides
• Fluvastatin
• Cholesterol

Topics

• Adult
• Anticholesteremic Agents (adverse effects, therapeutic use)
• Blood Pressure (drug effects)
• Cholesterol (blood)
• Cholesterol, HDL (blood)
• Cholesterol, LDL (blood)
• Fatty Acids, Monounsaturated (pharmacokinetics, therapeutic use)
• Female
• Fluvastatin
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (pharmacokinetics, therapeutic use)
• Hyperlipidemias (drug therapy, etiology)
• Indoles (pharmacokinetics, therapeutic use)
• Kidney Transplantation
• Male
• Middle Aged
• Postoperative Complications (drug therapy)
• Triglycerides (blood)